Addressing Vaccine Inequity - Covid-19 Vaccines as a Global Public Good

Affiliations

¹ From the Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom, and the Harvard T.H. Chan School of Public Health, Boston (D.J.H.); the Centre for the Aids Programme of Research in South Africa, Durban, and the Department of Epidemiology, Columbia Mailman School of Public Health, New York (S.A.K.); and the Wellcome Trust, London (J.J.F.).

Editorial

David J Hunter et al. N Engl J Med. 2022.

. 2022 Mar 24;386(12):1176-1179.

doi: 10.1056/NEJMe2202547. Epub 2022 Feb 23.

¹ From the Nuffield Department of Population Health, University of Oxford, Oxford, United Kingdom, and the Harvard T.H. Chan School of Public Health, Boston (D.J.H.); the Centre for the Aids Programme of Research in South Africa, Durban, and the Department of Epidemiology, Columbia Mailman School of Public Health, New York (S.A.K.); and the Wellcome Trust, London (J.J.F.).

No abstract available

Comment on

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC; C4591001 Clinical Trial Group. Polack FP, et al. N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10. N Engl J Med. 2020. PMID: 33301246 Free PMC article. Clinical Trial.